BOBO DONALD E JR 4

4 · Edwards Lifesciences Corp · Filed Jan 6, 2026

Form 4

Period: 2026-01-06

CVP,Strategy/Corp Development

Transactions

Exercise/Conversion
Common Stock
2026-01-06$59.26/sh+11,340$671,971→ 43,210.253 total
Sale
Common Stock
2026-01-06$84.62/sh−2,632$222,721→ 40,578.253 total
Sale
Common Stock
2026-01-06$85.98/sh−8,708$748,708→ 31,870.253 total
Exercise/Conversion
Employee Stock Option (Right to Acquire)
2026-01-06−11,340→ 34,020 total
Exercise: $59.26From: 2019-06-08Exp: 2026-05-07→ Common Stock (11,340 underlying)

Holdings

Footnotes (3)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.
[F2]This transaction was executed in multiple trades at prices ranging from $84.39 to $85.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $85.40 to $86.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file